Literature DB >> 572004

Chronic ECHO type 5 virus meningoencephalitis in X-linked hypogammaglobulinemia: treatment with immune plasma.

J B Bodensteiner, H H Morris, J T Howell, S S Schochet.   

Abstract

A patient with X-linked hypogammaglobulinemia developed chronic meningoencephalitis. ECHO virus type 5 was repeatedly cultured from cerebrospinal fluid (CSF). Infusions of high-titer, specific plasma resulted in clinical improvement, but failed to eradicate the virus. After more intensive plasma infusions, the virus could not be cultured from the CSF. The patient died 8 months after institution of intensive therapy. The cause of death was unknown. Autopsy showed persistence of perivascular and meningeal inflammation. Specific anti-ECHO-virus-5 plasma was shown to be more effective in lowering CSF ECHO-virus titers than was plasma without anti-ECHO-virus antibody.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 572004     DOI: 10.1212/wnl.29.6.815

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  3 in total

1.  Successful treatment of echovirus meningoencephalitis in sex-linked agammaglobulinaemia by intrathecal and intravenous injection of high titre gammaglobulin.

Authors:  H Kondoh; K Kobayashi; Y Sugio; T Hayashi
Journal:  Eur J Pediatr       Date:  1987-11       Impact factor: 3.183

Review 2.  HLA restriction of human cytotoxic T cells.

Authors:  A J McMichael
Journal:  Springer Semin Immunopathol       Date:  1980-05

Review 3.  Integrative overview of antibodies against SARS-CoV-2 and their possible applications in COVID-19 prophylaxis and treatment.

Authors:  Norma A Valdez-Cruz; Enrique García-Hernández; Clara Espitia; Laura Cobos-Marín; Claudia Altamirano; Carlos G Bando-Campos; Luis F Cofas-Vargas; Enrique W Coronado-Aceves; Ricardo A González-Hernández; Pablo Hernández-Peralta; Daniel Juárez-López; Paola A Ortega-Portilla; Sara Restrepo-Pineda; Patricio Zelada-Cordero; Mauricio A Trujillo-Roldán
Journal:  Microb Cell Fact       Date:  2021-04-22       Impact factor: 5.328

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.